Paper - WANFANG MED ONLINE

You Position: Home > Paper

生殖器疱疹疫苗的研究进展

( views:549, downloads:16 )

Author:: No author available

Journal Title:: FOREIGN MEDICAL SCIENCES(SECTION OF DERMATOLOGY AND VENEREOLOGY)

Issue:: 3

DOI:: 10.3760/cma.j.issn.1673-4173.2003.03.020

Key Word:: 疱疹,生殖器;单纯疱疹病毒属;疫苗

Abstract：生殖器疱疹的发病率逐年升高,是HIV经性传播感染的主要促进因素之一,已成为严重的公共卫生问题.疱疹病毒疫苗是预防生殖器疱疹感染的重要措施,随着基因工程技术的发展,越来越多的手段用于疫苗的研制.综述减毒活疫苗、复制受限疫苗、DISC疫苗、亚单位疫苗、DNA疫苗的研究进展.

Reference

[1]Kim JJ,Ciccarelli RB,Wolf MW,etc.IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge.[J].1999,162(5).
[2]Sin, J.-I.,Kim, J. J.,Zhang, D.,etc.Modulation of Cellular Responses by Plasmid CD40L: CD40L Plasmid Vectors Enhance Antigen-Specific Helper T Cell Type 1 CD4^+ T Cell-Mediated Protective Immunity against Herpes Simplex Virus Type 2 in Vivo[J].2001,12(9).
[3]Elkins KL,Nass PH,Weir JP.Protective immunity against herpes simplex virus generated by DNA vaccination compared to natural infection[J].2001,19(11).
[4]C. C. Smith,T. Peng.The PK Domain of the Large Subunit of Herpes Simplex Virus Type 2 Ribonucleotide Reductase (ICP10) Is Required for Immediate-Early Gene Expression and Virus Growth[J].1998,72(11).
[5]J E, Strasser,R L, Arnold,C, Pachuk,etc.Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs.[J].2000,182(5).
[6]Corey L,Burke RL,Douglas JM Jr,etc.Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group (see comments)[J].1999,282(4).
[7]Stanberry LR,Spruance SL,Cunningham AL,etc.Glycoprotein-D-adjuvant vaccine to prevent genital herpes.[J].2002,347(21).
[8]Sin JI.,Kim JJ.,Pachuk C.,etc.DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo[J].2000,74(23).
[9]J R, Simms,A W, Heath,R, Jennings.Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs.[J].2000,181(4).
[10]Eo SK,Lee S,Kumaraguru U,etc.Immunopotentiation of DNA vaccine against herpes simplex virus viaco-delivery of plasmid DNA expressing CCR7 ligands[J].2001,19(32).
[11]W C Manning.Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D.[J].1997,71(10).
[12]Kulka M,Smith CC,Aurelian L,etc.A growth and latency compromised herpes simplex virus type 2 mutant (ICP10 Delta PK) has prophylactic and therapeutic protective activity in guinea pigs[J].2001,19(15).
[13]Smith CC.,Kokuba H.,Aurelian L..Vaccine potential of a herpes simplex virus type 2 mutant deleted in thePK domain of the large subunit of ribonucleotide reductase (ICP10)[J].1999,17(15).
[14]Stanberry, Lawrence R.,Cunningham, Anthony L.,Mindel, Adrian,etc.Prospects for Control of Herpes Simplex Virus Disease through Immunization.[J].2000,30(3).
[15]Brentjens MH,Yeung Yue KA,Lee PC,etc.Herpes simplex viruses 1 and 2.[J].2002,20(2).
[16]Connelly BL.,Bourne N.,Cohen J.,etc.Immunization with Recombinant Varicella-Zoster Virus Expressing Herpes Simplex Virus Type 2 Glycoprotein D Reduces the Severity of Genital Herpes in Guinea Pigs[J].1995,69(12).
[17]Dacosta XJ. Bourne N. Stanberry LR. Knipe DM..Construction and Characterization of a Replication-Defective Herpes Simplex Virus 2 Icp8 Mutant Strain and Its Use in Immunization Studies in a Guinea Pig Model of Genital Disease[J].1997,232(1).
[18]Mbizvo EM,Chirenje MZ,Hussain A,etc.Association of herpes simplex virus type 2 with the human immunodeficiency virus among urban women in Zimbabwe.[J].2002,13(5).
[19]Geiss BJ.,Morrison LA.,Leib DA.,etc.Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain[J].2000,74(23).
[20]J. Fló,S. Tisminetzky,F. Baralle.Modulation of the immune response to DNA vaccine by co‐delivery ofcostimulatory molecules[J].2000,100(2).
[21]Corey L,Handsfield HH.Genital herpes and public health: addressing a global problem.[J].2000,283(6).
[22]Entwisle C,Boursnell ME,Roberts C,etc.A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.[J].1997,175(1).
[23]Bernstein DI.,Stanberry LR..Herpes simplex virus vaccines[J].1999,17(13).
[24]Da Costa-X,Kramer MF,Zhu J,etc.Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.[J].2000,74(17).
[25]Morrison LA.Vaccines against genital herpes: progress and limitations.[J].2002,62(8).
[26]Malgorzata Gierynska,Uday Kumaraguru,Seong-Kug Eo,etc.Induction of CD8 T-Cell-Specific Systemic and Mucosal Immunity against Herpes Simplex Virus with CpG-Peptide Complexes[J].2002,76(13).